A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy [EXTENSION OF 700044445]

Trial Profile

A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy [EXTENSION OF 700044445]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Bronchiolitis obliterans; Lung transplant rejection
  • Focus Adverse reactions
  • Sponsors PARI Pharma GmbH
  • Most Recent Events

    • 03 Sep 2013 Status changed from recruiting to discontinued as reportedby ClinicalTrials.gov record.
    • 03 Sep 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01439958).
    • 10 Aug 2013 This trial has been suspended in Germany, according to the European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top